Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders.

AIDS. 1990 Dec;4(12):1205-12. Unique Identifier : AIDSLINE MED/91207613
Gryllis C; Wainberg MA; Gornitsky M; Brenner B; Lady Davis Institute of the Jewish General Hospital, Montreal,; Quebec, Canada.

Abstract: We have compared the relative ability of lymphokine-activated killer (LAK) cells derived from peripheral blood of HIV-seropositive people, AIDS subjects, and healthy controls, to lyse a panel of natural killer (NK)-sensitive and NK-resistant tumor and virally-infected targets. We have found that LAK cells derived from HIV-seropositive populations show a significant, albeit reduced, capacity to lyse U937, K562, and RAJI target cell lines, in comparison with similarly derived cells from healthy controls. The reductions in LAK activity in both HIV-seropositive asymptomatic and AIDS populations reflect a significant reduction in cytotoxic potential of individual LAK cells. The maximal LAK cytotoxic potentials of control, asymptomatic seropositive, and AIDS populations are comparable. LAK cells derived from HIV-seropositive populations show an enhanced capacity to lyse HIV-infected U937 targets relative to their uninfected counterparts. These enhancements in HIV-infected U937 versus U937 cytolysis arise from increases in the maximal cell-mediated cytolytic plateau. Depletion of NK (CD56+) lymphocytes from peripheral blood prior to LAK cell generation markedly diminishes subsequent specific and total inducible LAK activity. In some subjects, peripheral blood T-cell depletion prior to LAK cell generation results in LAK cells that are subsequently enriched for cytolytic activity, whereas in other subjects similar T-cell depletion impairs inducible LAK cell responses.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/*IMMUNOLOGY Analysis of Variance Cytotoxicity, Immunologic Human HIV Seropositivity/*IMMUNOLOGY Killer Cells, Lymphokine-Activated/*IMMUNOLOGY Killer Cells, Natural/IMMUNOLOGY Opportunistic Infections/*COMPLICATIONS Support, Non-U.S. Gov't Tumor Cells, Cultured JOURNAL ARTICLE

910830
M9180958

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .